AbbVie (ABBV) Cash & Current Investments (2012 - 2026)

AbbVie has disclosed Cash & Current Investments across 15 years of filings, most recently posting $9.4 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 81.43% year-over-year to $9.4 billion; the TTM figure through Mar 2026 stood at $9.4 billion (up 81.43% YoY), while the FY2025 annual figure was $5.3 billion, down 5.36% from the prior year.
• Cash & Current Investments improved to $9.4 billion in Q1 2026, from $5.3 billion in the prior quarter.
• Over the last five years, Cash & Current Investments for ABBV reached as high as $18.1 billion in Q1 2024 and fell as low as $5.2 billion in Q1 2025.
• The 5-year median for Cash & Current Investments is $8.8 billion (2023), against an average of $9.2 billion.
• Annual changes were most pronounced in 2024 — Cash & Current Investments surged 168.8% — and 2025, when it slumped 71.35%.
• A 5-year view of Cash & Current Investments shows it stood at $9.2 billion in 2022, then soared by 38.87% to $12.8 billion in 2023, then tumbled by 56.66% to $5.6 billion in 2024, then dropped by 5.36% to $5.3 billion in 2025, then soared by 78.64% to $9.4 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $9.4 billion, $5.3 billion, and $5.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.